歌禮製藥(01672.HK)抑制劑ASC50治療銀屑病美國試驗完成首批給藥
歌禮製藥(01672.HK)宣布,其自主研發的口服小分子白細胞介素-17(IL-17)靶向抑制劑ASC50,在美國進行的隨機、雙盲和安慰劑對照的一期臨床試驗已完成首批健康受試者給藥。該試驗旨在評估ASC50治療銀屑病的安全性、耐受性及初步療效,試驗於美國多個中心進行,涵蓋健康受試者及輕中度斑塊狀銀屑病患者。
公司表示,臨床前數據顯示ASC50具有更高的口服暴露量、更長的半衰期及強效藥理作用,有望成為治療銀屑病的同類最佳(best-in-class)每日一次口服藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.